Deutsche Bank initiated coverage of AbbVie with a Hold rating and $150 price target. The analyst thinks macro headwinds and facial filler competition exposes AbbVie to miss its fiscal 2025 guidance of high-single digit revenue growth. The firm believes Skyrizi/Rinvoq’s will still be at the beginning portion of its inflection and may not overcome Humira’s erosion.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ABBV:
- Caribou Biosciences reports Q3 EPS (12c), consensus (42c)
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Aldeyra in option pact with AbbVie for up to $300M potential payment
- Early notable gainers among liquid option names on October 30th
- AbbVie upgraded, Cisco downgraded: Wall Street’s top analyst calls